Titan Pharma Inc (TTNP) 0.4800 $TTNP
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 31.32 (+0.26), ADMS: 16.10 (+1.45), TEVA: 57.09 (+0.33), ACOR: 39.14 (+0.74), PRTA: 20.14 (+1.41), NDRM: 5.90 (-0.19)
Titan Pharmaceuticals to Present at LD Micro Conference
Marketwired - Mon Dec 01, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that its President, Sunil Bhonsle, will present at the 7th annual LD Micro "Main Event" Micro-Cap Growth Conference on Thursday, Dec. 4 at 8:30 a.m. PT. The conference will be held at the Luxe Sunset Bel Air Hotel, in Los Angeles, Calif.
Enrollment complete in Probuphine Phase 3
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 9:03AM CST
Titan Pharmaceuticals Announces Completion of Enrollment in Phase 3 Study of Probuphine for Opioid Dependence
Marketwired - Thu Nov 20, 5:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced completion of enrollment in the ongoing Phase 3 study of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. Study completion is expected to be on schedule by the middle of 2015, paving the way for resubmission of the New Drug Application (NDA) for Probuphine with the U.S. Food and Drug Administration (FDA) later in the year.
Titan Pharmaceuticals (TTNP) Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:01PM CST
Titan Pharmaceuticals EPS and revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:38AM CST
Titan Pharmaceuticals Announces Third Quarter 2014 Financial Results
Marketwired - Thu Nov 13, 6:02AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, today reported financial results for the third quarter ended Sept. 30, 2014.
Titan Pharmaceuticals Appoints Two New Board Members
Marketwired - Tue Nov 11, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has appointed life sciences industry veterans Joseph A. Akers and James McNab Jr. to its board of directors. Mr. Akers, a former Bayer HealthCare executive, and Mr. McNab, chairman and co-founder of Curis, Inc., together bring extensive product development, commercialization, finance and corporate governance experience to Titan.
CRIS: 1.29 (+0.04)
Titan Pharma reports November 14
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:12AM CST
Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2014 Financial Results
Marketwired - Fri Nov 07, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 11 a.m. EST / 8 a.m. PST on Friday, Nov. 14, 2014 to discuss the company's financial results as of Sept. 30, 2014. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the third quarter and financial results will be included in a press release to be issued prior to the call.
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 340.89 (+5.13), MNOV: 3.04 (unch), CHTP: 6.52 (-0.03), ADMS: 16.10 (+1.45), ACOR: 39.14 (+0.74), BCLI: 3.85 (+0.22), BSX: 13.13 (+0.07), IPXL: 31.32 (+0.26), AVNR: 16.91 (+0.01), ACAD: 30.95 (+0.78), CVTS: (), MRK: 57.46 (+0.25), TEVA: 57.09 (+0.33), PRTA: 20.14 (+1.41), PRAN: 1.74 (-0.02), FOLD: 7.94 (+0.06), CUR: 2.70 (+0.07)
Titan Pharmaceuticals Announces Pricing of Public Offering
Marketwire - Fri Oct 03, 7:37AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term delivery technology, today announced the pricing of an underwritten public offering of 21,000,000 units at an offering price of $0.50 per unit, with each unit consisting of one share of common stock and 0.75 of a warrant, each full warrant to purchase one share of common stock at an exercise price of $0.60 per share. Titan expects to receive gross proceeds of $10.5 million from this offering, before deducting underwriting discounts, commissions and other related expenses.
Titan Pharmaceuticals Announces Enrollment Reaches Halfway Mark in Phase 3 Study of Probuphine for Opioid Dependence
Marketwire - Tue Sep 23, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that patient enrollment in the Phase 3 study of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence, has reached the halfway mark. Titan's partner, Braeburn Pharmaceuticals, is sponsoring the study and expects it to be fully enrolled before the end of this year, with study completion on schedule by the middle of 2015. The study is designed to support resubmission of the New Drug Application for Probuphine with the U.S. Food and Drug Administration, which is expected later in 2015.
Titan Pharmaceuticals to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Marketwire - Wed Sep 03, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence, Parkinson's Disease, and other serious medical disorders, today announced that Titan President Sunil Bhonsle will present at the Rodman & Renshaw 16th Annual Global Investor Conference at the New York Palace Hotel in New York City on Sept. 10 from 9:35-10 a.m. The presentation will take place in the Kennedy II Salon.
IPOs and Transactions: August 25 - 29
PR Newswire - Tue Sep 02, 12:57PM CDT
Vintage, the regulatory compliance and shareholder communications division of PR Newswire, has released its weekly IPO and Transaction summary.
BNCN: 17.43 (-0.24), ROX: 1.45 (-0.04), GPT: 6.96 (+0.06)
Titan Pharmaceuticals Announces Second Quarter 2014 Financial Results
Marketwire - Wed Aug 13, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence and other serious medical disorders, today reported financial results for the second quarter ended June 30, 2014.
Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2014 Financial Results
Marketwire - Thu Aug 07, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Thursday, Aug. 14, 2014 to discuss the company's financial results as of June 30, 2014. The call will be hosted by Sunil Bhonsle, president; Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the second quarter and financial results will be included in a press release to be issued prior to the call.
Titan Pharmaceuticals Announces First Patient Enrollment in Clinical Study of Probuphine for Opioid Dependence
Marketwire - Mon Jul 21, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced enrollment of the first patients in the Phase 3 clinical study to support resubmission of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The study, which is expected to be completed by the middle of 2015, is designed to address key questions posed by the U.S. Food and Drug Administration (FDA) in its complete response letter last year after review of the original NDA. Titan's partner Braeburn Pharmaceuticals is sponsoring the trial and anticipates resubmission of the NDA to the FDA in late 2015.
Highline Research Advisors Initiates on Titan Pharmaceuticals with a Buy Rating
Thomson Reuters ONE - Mon Jul 07, 9:44AM CDT
SAN FRANCISCO - July 7, 2014 -Michael Higgins from Highline Research Advisors, part of Financial Entrepreneur Platform at Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it has initiated equity research coverage of Titan Pharmaceuticals, Inc. (OTCQB: TTNP) with a Buy rating and a $3.00 price target.
CSE: 2014-0205-Name and Symbol Change-Synergy Acquisition Corp. (QMP)
Marketwire Canada - Wed Feb 12, 10:20AM CST
Synergy Acquisition Corp. has announced a name change to Genius Properties Ltd.
USTR: 42.04 (-0.13), ONCY: 0.49 (unch), NVO: 43.80 (+1.08)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 31.32 (+0.26), ADMS: 16.10 (+1.45), TEVA: 57.09 (+0.33), ACOR: 39.14 (+0.74), PRTA: 20.14 (+1.41), NDRM: 5.90 (-0.19)
Titan Pharmaceuticals to Present at LD Micro Conference
Marketwired - Mon Dec 01, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that its President, Sunil Bhonsle, will present at the 7th annual LD Micro "Main Event" Micro-Cap Growth Conference on Thursday, Dec. 4 at 8:30 a.m. PT. The conference will be held at the Luxe Sunset Bel Air Hotel, in Los Angeles, Calif.
Enrollment complete in Probuphine Phase 3
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 9:03AM CST
Titan Pharmaceuticals Announces Completion of Enrollment in Phase 3 Study of Probuphine for Opioid Dependence
Marketwired - Thu Nov 20, 5:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced completion of enrollment in the ongoing Phase 3 study of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. Study completion is expected to be on schedule by the middle of 2015, paving the way for resubmission of the New Drug Application (NDA) for Probuphine with the U.S. Food and Drug Administration (FDA) later in the year.
Titan Pharmaceuticals (TTNP) Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:01PM CST
Titan Pharmaceuticals EPS and revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:38AM CST
Titan Pharmaceuticals Announces Third Quarter 2014 Financial Results
Marketwired - Thu Nov 13, 6:02AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, today reported financial results for the third quarter ended Sept. 30, 2014.
Titan Pharmaceuticals Appoints Two New Board Members
Marketwired - Tue Nov 11, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has appointed life sciences industry veterans Joseph A. Akers and James McNab Jr. to its board of directors. Mr. Akers, a former Bayer HealthCare executive, and Mr. McNab, chairman and co-founder of Curis, Inc., together bring extensive product development, commercialization, finance and corporate governance experience to Titan.
CRIS: 1.29 (+0.04)
Titan Pharma reports November 14
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:12AM CST
Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2014 Financial Results
Marketwired - Fri Nov 07, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 11 a.m. EST / 8 a.m. PST on Friday, Nov. 14, 2014 to discuss the company's financial results as of Sept. 30, 2014. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the third quarter and financial results will be included in a press release to be issued prior to the call.
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 340.89 (+5.13), MNOV: 3.04 (unch), CHTP: 6.52 (-0.03), ADMS: 16.10 (+1.45), ACOR: 39.14 (+0.74), BCLI: 3.85 (+0.22), BSX: 13.13 (+0.07), IPXL: 31.32 (+0.26), AVNR: 16.91 (+0.01), ACAD: 30.95 (+0.78), CVTS: (), MRK: 57.46 (+0.25), TEVA: 57.09 (+0.33), PRTA: 20.14 (+1.41), PRAN: 1.74 (-0.02), FOLD: 7.94 (+0.06), CUR: 2.70 (+0.07)
Titan Pharmaceuticals Announces Pricing of Public Offering
Marketwire - Fri Oct 03, 7:37AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term delivery technology, today announced the pricing of an underwritten public offering of 21,000,000 units at an offering price of $0.50 per unit, with each unit consisting of one share of common stock and 0.75 of a warrant, each full warrant to purchase one share of common stock at an exercise price of $0.60 per share. Titan expects to receive gross proceeds of $10.5 million from this offering, before deducting underwriting discounts, commissions and other related expenses.
Titan Pharmaceuticals Announces Enrollment Reaches Halfway Mark in Phase 3 Study of Probuphine for Opioid Dependence
Marketwire - Tue Sep 23, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that patient enrollment in the Phase 3 study of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence, has reached the halfway mark. Titan's partner, Braeburn Pharmaceuticals, is sponsoring the study and expects it to be fully enrolled before the end of this year, with study completion on schedule by the middle of 2015. The study is designed to support resubmission of the New Drug Application for Probuphine with the U.S. Food and Drug Administration, which is expected later in 2015.
Titan Pharmaceuticals to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Marketwire - Wed Sep 03, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence, Parkinson's Disease, and other serious medical disorders, today announced that Titan President Sunil Bhonsle will present at the Rodman & Renshaw 16th Annual Global Investor Conference at the New York Palace Hotel in New York City on Sept. 10 from 9:35-10 a.m. The presentation will take place in the Kennedy II Salon.
IPOs and Transactions: August 25 - 29
PR Newswire - Tue Sep 02, 12:57PM CDT
Vintage, the regulatory compliance and shareholder communications division of PR Newswire, has released its weekly IPO and Transaction summary.
BNCN: 17.43 (-0.24), ROX: 1.45 (-0.04), GPT: 6.96 (+0.06)
Titan Pharmaceuticals Announces Second Quarter 2014 Financial Results
Marketwire - Wed Aug 13, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence and other serious medical disorders, today reported financial results for the second quarter ended June 30, 2014.
Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2014 Financial Results
Marketwire - Thu Aug 07, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Thursday, Aug. 14, 2014 to discuss the company's financial results as of June 30, 2014. The call will be hosted by Sunil Bhonsle, president; Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the second quarter and financial results will be included in a press release to be issued prior to the call.
Titan Pharmaceuticals Announces First Patient Enrollment in Clinical Study of Probuphine for Opioid Dependence
Marketwire - Mon Jul 21, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced enrollment of the first patients in the Phase 3 clinical study to support resubmission of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The study, which is expected to be completed by the middle of 2015, is designed to address key questions posed by the U.S. Food and Drug Administration (FDA) in its complete response letter last year after review of the original NDA. Titan's partner Braeburn Pharmaceuticals is sponsoring the trial and anticipates resubmission of the NDA to the FDA in late 2015.
Highline Research Advisors Initiates on Titan Pharmaceuticals with a Buy Rating
Thomson Reuters ONE - Mon Jul 07, 9:44AM CDT
SAN FRANCISCO - July 7, 2014 -Michael Higgins from Highline Research Advisors, part of Financial Entrepreneur Platform at Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it has initiated equity research coverage of Titan Pharmaceuticals, Inc. (OTCQB: TTNP) with a Buy rating and a $3.00 price target. CSE: 2014-0205-Name and Symbol Change-Synergy Acquisition Corp. (QMP)
Marketwire Canada - Wed Feb 12, 10:20AM CST
Synergy Acquisition Corp. has announced a name change to Genius Properties Ltd.
USTR: 42.04 (-0.13), ONCY: 0.49 (unch), NVO: 43.80 (+1.08)
